Pancreatic cancer is notoriously hard to treat, often resisting therapies that target its most common mutations. Researchers have now uncovered a hidden three-part loop that fuels tumor growth, ...

Adding elraglusib to chemotherapy significantly increases overall survival in patients with previously untreated metastatic PDAC.

Survival is not a victory parade; it is a long-term contract with chronic illness.

Please provide your email address to receive an email when new articles are posted on . Antibiotic receipt in the month before or after gemcitabine treatment improved survival in metastatic pancreatic ...

The annual Prospectors & Developers Association of Canada (PDAC) convention is returning this year from March 3 to 6, and it comes as countries around the world take steps to secure supply of key ...

Furthermore, a near-doubling of 12-month survival was also achieved with the elraglusib regimen vs GnP alone (44.4% vs 22.3%), and at 24 months, the survival rate was nearly 5 times higher in the ...

A novel discovery in the field of pancreatic cancer treatment has been unveiled, revealing the epigenetic silencing of BEND4 as a potential synthetic lethal marker for enhancing the efficacy of ATM ...